In the fifth and final part of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, highlights the importance of human oversight when using artificial intelligence to aid in decision making.
In part 4 of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, spotlights the importance of considering the experience of patients when integrating artificial intelligence as well as some of the benefits they will see from it.
In part 3 of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, discusses the importance of collaboration and data sharing in advancing the use of technology.
In part 2 of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes.
In part 1 of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, gives a broad overview of the use of artificial intelligence in clinical development and how regulatory bodies are viewing it.
In part 2 of this video interview with ACT editor Andy Studna, Tirisham Gyang, MD, assistant professor of neurology at The Ohio State University discusses how industry can effectively enroll patients from underrepresented populations into their trials.
In part 1 of this video interview with ACT editor Andy Studna, Tirisham Gyang, MD, assistant professor of neurology at The Ohio State University discusses how new research is changing the way industry recognizes multiple sclerosis in non-white populations.
In the fourth and final part of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the key features of O2P as well as plans for further development of the hydrocodone prodrug.
In part 3 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the development journey of his company's hydrocodone prodrug, O2P.
In part 2 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses what industry should be keeping top of mind when it comes to designing and executing pain clinical studies.
In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.
In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the role of technology in addressing the data gap in women's health research and encourages women interested in healthcare to go for it.
In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.
In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to participating in clinical trials.
In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, talks about the ethical considerations that need to be addressed when implementing new technologies for collecting and analyzing patient data in clinical trials, while ensuring patient privacy.
In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses new technologies that can help personalize the clinical trial experience for diverse patient populations.
In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses the development of new technologies helping to foster trust and informed decision-making throughout the clinical trial process.
In this Applied Clinical Trials video interview, Julia Lakeland, Chief Product Officer, uMotif, discusses what kinds of technologies can be developed to improve patient engagement while still maintaining data integrity.
Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, speak on what they think the future looks like when it comes to streamlining and improving the clinical trial imaging landscape.
In this Applied Clinical Trials video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report.
Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, discuss adapting to the specific needs and considerations of trials with cardiac, neuro, and pulmonary specialties.
Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.
Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, provide commentary on current obstacles associated with clinical trials and how their company is addressing them.
In an interview with ACT Editor Andy Studna, Gadi Saarony, CEO, Advarra, offers his thoughts on the status of the pharmaceutical industry improving diversity in clinical trials.
Christian Olsen, VP, Industry Principal of Biologics at Dotmatics, discusses how artificial intelligence along with other technologies are being used to shorten the drug discovery funnel and reduce research costs.
In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.
In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.
In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.
